Free Trial
→ My public warning after 55 years of watching the markets (From Weiss Ratings) (Ad)tc pixel
NASDAQ:XCUR

Exicure Q2 2025 Earnings Results & Report

Exicure logo
$1.06 -0.05 (-4.50%)
Closing price 03:59 PM Eastern
Extended Trading
$1.10 +0.04 (+3.40%)
As of 06:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Exicure reported Q2 2025 earnings on August 8, 2025. The company reported EPS of -$0.41.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
After Market Closes

Exicure EPS Results

Actual EPS
-$0.41
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Exicure Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Exicure's next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules.

Conference Call Resources

Exicure Q2 2025 Earnings FAQ

Exicure (NASDAQ:XCUR) reported earnings of -$0.41 per share for Q2 2025. The report was announced on Friday, August 8, 2025.

Exicure's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Exicure on the company's earnings history page.

Exicure Earnings Headlines

Exicure Inks $4.8M Asset Deal to Strengthen Balance Sheet
November 11 at 10:27 AM  |  benzinga.comhttps://www.benzinga.com/m-a/26/11/63144891/exicure-inks-4-8m-asset-deal-to-strengthen-balance-sheet?utm_source=snapi
Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion
November 10 at 8:21 PM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/exicure-inc-announces-agreement-to-sell-gpc-100-program-assets-to-gpcrt-inc-for-krw-6-5-billion-1036744265
A free stock pick, from me to you
Elon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.tc pixel
November 12 at 1:00 AM  |  Behind the Markets (Ad)
Exicure Announces Agreement to Sell GPC-100 Program Assets to GPCRT for Approximately $4.8 Million
November 10 at 4:10 PM  |  quiverquant.comQ
Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion
November 10 at 3:50 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/10/3400161/33289/en/exicure-inc-announces-agreement-to-sell-gpc-100-program-assets-to-gpcrt-inc-for-krw-6-5-billion.html
Exicure (XCUR) Projected to Announce Earnings on Thursday
November 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31180033
See More Exicure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Exicure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exicure and other key companies, straight to your email.

About Exicure

Exicure (NASDAQ:XCUR) is a biotechnology company that historically focused on developing therapeutics based on spherical nucleic acid (SNA) technology. The company’s platform was designed to use three-dimensional arrangements of nucleic acids to target specific genetic and biological pathways, with potential applications in diseases that are difficult to address using conventional drug-delivery approaches.

Exicure’s development programs included candidates for genetic and neurological disorders, as well as dermatological and other conditions. Its research portfolio has included programs aimed at Friedreich’s ataxia and other diseases involving abnormal gene expression. The company has also explored SNA-based treatments for skin and hair disorders and partnered with larger pharmaceutical companies on selected development efforts.

Exicure was founded in 2011 and was based in the Chicago, Illinois, area. Its programs were primarily directed toward the development of novel medicines rather than the sale of marketed products. Public disclosures in later years described significant operational and development challenges, and information about the company’s current activities and leadership is limited.

View Exicure Profile
Earnings Tools